LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
LifeVantage Corporation reported weaker results for the third fiscal quarter ended March 31, 2026. Revenue was $43.7 million, down 25.2% from $58.4 million a year earlier, driven mainly by lower sales of the MindBody GLP-1 System, partly offset by the LoveBiome acquisition.
Gross margin remained high at 79.0%, but operating income declined to $1.7 million from $4.1 million. Net income fell to $1.4 million or $0.11 per diluted share, versus $3.5 million or $0.26. Adjusted EBITDA decreased to $3.2 million from $6.4 million.
Active accounts dropped to 109,000, down 22.1% year over year, reflecting fewer consultants and customers. The company generated $5.5 million of operating cash flow in the first nine months, held $12.5 million in cash with no debt, and raised its quarterly dividend to $0.05 per share, up 11.1%. Management now expects full-year fiscal 2026 revenue, adjusted EBITDA and adjusted EPS to be near the lower end of its prior guidance range.
LifeVantage Corporation reported weaker results for the third fiscal quarter ended March 31, 2026. Revenue was $43.7 million, down 25.2% from $58.4 million a year earlier, driven mainly by lower sales of the MindBody GLP-1 System, partly offset by the LoveBiome acquisition.
Gross margin remained high at 79.0%, but operating income declined to $1.7 million from $4.1 million. Net income fell to $1.4 million or $0.11 per diluted share, versus $3.5 million or $0.26. Adjusted EBITDA decreased to $3.2 million from $6.4 million.
Active accounts dropped to 109,000, down 22.1% year over year, reflecting fewer consultants and customers. The company generated $5.5 million of operating cash flow in the first nine months, held $12.5 million in cash with no debt, and raised its quarterly dividend to $0.05 per share, up 11.1%. Management now expects full-year fiscal 2026 revenue, adjusted EBITDA and adjusted EPS to be near the lower end of its prior guidance range.
LifeVantage Corporation reported lower sales and earnings for the quarter and nine months ended March 31, 2026. Quarterly net revenue fell to $43.7 million from $58.4 million, mainly from weaker MindBody GLP-1 System® demand in the Americas. Net income declined to $1.4 million from $3.5 million, though the business remained profitable.
For the nine months, revenue decreased to $140.2 million from $173.4 million, and net income dropped to $3.8 million from $7.8 million. Active Accounts fell 22.1% year over year, while the new LoveBiome® line and ongoing stock repurchases and dividends showed continued investment in the brand and shareholders.
LifeVantage Corporation reported lower sales and earnings for the quarter and nine months ended March 31, 2026. Quarterly net revenue fell to $43.7 million from $58.4 million, mainly from weaker MindBody GLP-1 System® demand in the Americas. Net income declined to $1.4 million from $3.5 million, though the business remained profitable.
For the nine months, revenue decreased to $140.2 million from $173.4 million, and net income dropped to $3.8 million from $7.8 million. Active Accounts fell 22.1% year over year, while the new LoveBiome® line and ongoing stock repurchases and dividends showed continued investment in the brand and shareholders.
LifeVantage Corporation is implementing a planned CEO transition. Steven R. Fife will retire as President, Chief Executive Officer and director effective April 30, 2026, and will serve as an executive advisor through September 11, 2026 under a transition agreement that provides continued benefits and partial equity vesting.
Director Michael Beindorff will become Interim CEO from May 1 to August 4, 2026 under a consulting agreement paying $45,833 per month and will leave key board committees during this period. Effective August 5, 2026, the company will appoint industry veteran Terrence O. Moorehead as President, CEO and director with an annual base salary of $850,000, target cash bonus equal to 100% of salary, and a guaranteed $425,000 bonus for the fiscal year ending June 30, 2027.
Moorehead’s equity package includes time-based RSUs valued at $2.8 million and PSUs valued at $4.7 million, with portions prorated for his initial year and PSUs tied to revenue and Adjusted EBITDA margin targets. If terminated without cause or he resigns for good reason, he is eligible for 18 months of salary continuation, health coverage reimbursement, prorated bonus and continued equity vesting, with enhanced benefits in a qualifying change in control scenario.
Lifevantage Corp General Counsel Alissa Neufeld reported a routine share withholding related to taxes. On April 1, 2026, 1,446 shares of Common Stock were disposed of at $4.20 per share as a tax-withholding disposition, not an open‑market sale. Following this transaction, she directly owns 114,086 shares of Lifevantage Common Stock.
Lifevantage Corp President and CEO Steven R. Fife reported a tax-related share disposition involving company common stock. On April 1, 2026, 8,180 shares were delivered at $4.20 per share to cover exercise price or tax obligations.
This transaction is classified as a tax-withholding disposition, not an open-market sale. After the adjustment, Fife directly holds 735,471 shares of Lifevantage common stock, indicating he retains a significant equity stake in the company following this routine administrative event.
Lifevantage Corp chief sales officer Kristen Cunningham reported a small share disposition related to tax withholding. On a compensation-related transaction, 1,928 shares of common stock were withheld at $4.20 per share to cover tax obligations.
After this event, she continues to directly hold 133,134 shares of Lifevantage common stock.
Lifevantage Corp Chief Financial Officer Aure Carl reported a routine tax-related share transfer. On April 1, 2026, he disposed of 1,527 shares of common stock at an indicated value of $4.20 per share to cover tax obligations by delivering shares.
After this tax-withholding disposition, Carl directly holds 156,915 shares of Lifevantage common stock. Because the transaction was for tax payment rather than an open-market sale, it reflects compensation-related administration rather than an active decision to buy or sell shares in the market.
The Capital Management Corporation reported beneficial ownership of 2,441,919 shares of LifeVantage Corporation, representing 19.1% of the company's common stock as of 03/31/2026. The filing is an Amendment No. 3 to a Schedule 13G/A and is signed by Pamela C. Simms as Compliance Officer.
The filing shows sole voting power over 2,406,719 shares and sole dispositive power over 2,441,919 shares. The filing lists The Capital Management Corporation as the reporting entity and provides its Virginia principal business address.
Lifevantage Corp director Lewis Darwin reported an open-market purchase of common stock. On this transaction date, he bought 1,055 shares at $5.23 per share, increasing his direct holdings to 136,563 shares. This filing shows a modest increase in his personal investment in the company.